StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Mizuho 'Encouraged' by Pfizer (PFE) COVID-19 Vaccine Data
July 20, 2020 10:57 AM
Mizuho Securities analyst Vamil Divan reiterated a Buy rating and $38.00 price target on Pfizer (NYSE: PFE), citing continued positive ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Next Articles
Morgan Stanley Reiterates Equalweight Rating on Pfizer (PFE) Following COVID Vaccine Update
July 21, 2020 8:42 AM
Moderna (MRNA) Trades Lower after Pfizer (PFE) and BioNTech (BNTX) Announce Early Positive Update from German Phase 1/2 COVID-19 Vaccine Study, Including First T Cell Response Data
July 20, 2020 8:47 AM
Pfizer (PFE), BioNTech SE (BNTX) Announce Early Positive Update from German Phase 1/2 COVID-19 Vaccine Study
July 20, 2020 8:46 AM
Pfizer and BioNTech Announce Early Positive Update from German Phase 1/2 COVID-19 Vaccine Study, Including First T Cell Response Data
July 20, 2020 8:46 AM
Pfizer (PFE), BioNTech (BNTX) Gain on Paper Discussing Ph1/2 Trial Results of its COVID-19 Vaccine
July 20, 2020 8:37 AM
Wall Street closes higher, Nasdaq sets record as potential vaccines show promise
July 20, 2020 6:53 AM
Pfizer (PFE), BioNTech SE (BNTX) Report Agreement with the U.K. for 30M Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2
July 20, 2020 6:00 AM
